KRAS and neoplasm: In their recently published article, Zhou et al. developed a high-affinity, selective, long-acting, non-covalent KRAS<sup>G12D</sup>-specific inhibitor and, further combined with the proteasome inhibitor carfilzomib, found that this protocol can achieve the purpose of killing mutant cell lines and inhibiting tumor growth in vitro and in vivo.